Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis

British Medical Journal

Volumn 319, Issue 7224, 1999, Pages 1529-1533

  Forbes, Raeburn B ^a,d   Lees, Ann ^b   Waugh, Norman ^c   Swingler, Robert J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b Hawkhead Rd   (United Kingdom)

^c Scottish Hlth Purch Info Centre   (United Kingdom)

^d ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; INTERFERON BETA SERINE;

ARTICLE; COST UTILITY ANALYSIS; DATA ANALYSIS; DRUG COST; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MULTIPLE SCLEROSIS; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RELAPSE; WHEELCHAIR;

EID: 0033547631     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.319.7224.1529     Document Type: Article

References (39)

1. 1 IFNB Multiple Sclerosis Study Group. Interferon beta 1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomised, double blind, placebo controlled trial. Neurology 1993;43:655-61.
2. 2 Jacobs LD, Cookfair DL, Rudick RR, Herndon RM, Richet JR, Salazir AM, et al. Intramuscular interferon beta 1a for disease progression in relapsing multiple sclerosis. Ann Neurology 1996;39:285-94.
3. 3 PRISMS Study Group. Randomised double-blind placebo controlled study of interferon beta 1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
4. 4 European Study Group on Interferon beta-1b in Secondary Progressive Multiple Sclerosis. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-7.
5. 5 Richards RG. Interferon beta in multiple sclerosis. Clinical cost effectiveness falls at the first hurdle. BMJ 1996;313:1159.
6. 6 Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-11.
7. 7 Mooney G. Economics, medicine and health care. 2nd ed. Hemel Hempstead: Prentice Hall Europe, 1992:5-20.
8. 8 Poser CM, Paty DW, Scheinberg L, McDonald I, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neural 1983:13:227-31.
9. 9 Forbes RB, Swingler RJ. Estimating the prevalence of multiple sclerosis in the United Kingdom using capture recapture methodology. Am J Epidemiol 1999;149:1016-24.
10. 10 Evans JMM, McDevitt DC, MacDonald TM. The Tayside medicines monitoring unit (MEMO): a record-linkage system for pharmacovigilance. Pharmaceutical Med 1995;9:177-84.
11. 11 Gardner MJ, Altman DG. Calculating confidence intervals for proportions and their differences. In: Statistics with confidence. London: BMJ, 1989:28-33.
12. 12 Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112:1419-28.
13. 13 Tremlett HL, Luscombe DK, Wiles CM. Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom. J Neurol Neurosurg Psychiatry 1998;65:362-5.
14. 14 Holmes J, Madgwick T, Bates D. The cost of multiple sclerosis. Br J Med Econ 1995;8:181-93.
15. 15 Blumhardt L, Wood C. The economics of multiple sclerosis: a cost of illness study. Br J Med Econ 1996;10:99-118.
16. 16 O'Brien B. Multiple sclerosis. London: Office of Health Economics, 1987.
17. 17 Graham B, McGregor K. What does a GP consultation cost? Br J Gen Pract 1997;47:170-2.
18. 18 British Medical Association, Royal Pharmaceutical Society of Great Britain. British national formulary. Vol 30. London: BMA, RPSGB, 1995.
19. 19 McAlpine D, Compston N. Some aspects of the natural history of disseminated sclerosis. QJ Med 1952;21:135-67.
20. 20 EUROQOL Group. EuroQol - a new facility for the measurement of health related quality of life. Health Policy 1990;16:199-208.
21. 21 Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: results from a UK general population survey. York: Centre for Health Economics, University of York, 1995. (Discussion paper 133.)
22. 22 Sackett DL, Richardson WS, Rosenberg WMC, Haynes RB. How to practice and teach evidence based medicine. London: Churchill Livingstone, 1996.
23. 23 Altman DG. Confidence intervals for number needed to treat. BMJ 1998;317:1309-12.
24. 24 Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Ass J 1992;146:473-81.
25. 25 Goodkin DE. Interferon beta therapy for multiple sclerosis. Lancet 1998;352:1486-7.
26. 26 Freeman J, Johnson J, Rollinson S, Thompson A, Hatch J. Standards of healthcare for people with MS. London: Multiple Sclerosis Society of Great Britain and Northern Ireland, Neurorehabilitation and Therapy Services Directorate of the National Hospital for Neurology and Neurosurgery, 1997.
27. 27 Speak out: moving MS into the millennium. MS Matters 1998 Nov/Dec:12-3.
28. 28 Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis. 1. Cost of illness. Can J Neural Sci 1938;25:23-30.
29. 29 Holmes J. Avoidance of need for social care should also be taken into account BMJ 1997;314:601.
30. 30 Carton H, Loos R, Pacolet J, Versieck K, Vlietinck R. Utilisation and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium). J Neurol Ararosurg Psychiatry 1998;64:444-50.
31. 31 Stolp-Smith KA, Atkinson EJ, Campion ME, O'Brien PC, Rodriguez M. Health care utilization in multiple sclerosis. A population based study in Olmstead County, MM. Neurology 1998;50:1594-1600.
32. 32 Tolley KH, Whynes DK. Interferon-b in multiple sclerosis. Can we control its costs? Pharmacoeconomics 1997;11:210-5.
33. 33 Busch MP, Dodd RY, Lackritz EM, AuBúchon JP, Birkmeyer JD, Petersen JD. Value and cost-effectiveness of screening blood donors for antibody to hepatitis B core antigen as a way of detecting window-phase human immunodeficiency virus type 1 infections. The HIV Blood Donor Study Group. Transfusion 1997;37:1003-11.
34. 34 Gerard K, Mooney G. QALY league tables: handle with care. Health Econ 1993;2:59-64.
35. 35 Parkin D, McNamee P, Jacoby A, Miller P, Thomas S, Bates D. A cost utility study of interferon beta for multiple sclerosis. Health Tecknol Assessment 1998:2(4).
36. 36 Brown MG, Murray TJ, Fisk JD, Sketris IS, Schwartz CE, Blanc JCL. A therapeutic and economic assessment of Betaferon in multiple sclerosis. Halifax: Dalhousie University, 1996.
37. 37 Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health related quality of life measure for multiple sclerosis. Quality Life Res 1995;4:187-206.
38. 38 Holmes J, Young C, Reti M. Quality of life in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:420.
39. 39 Vickrey BG, Hays RD, Genovese BJ, Myers LW, Ellison GW. Comparison of generic to disease-targeted health related quality of life measures for multiple sclerosis. J Clin Epidemiol 1997;50:5457-69.